Diligence memo · auto-generated · as of July 2, 2026
Octave Bioscience Inc
Octave Bioscience Inc has raised $106M over 5 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Octave Bioscience Inc operates in Biotech, based in MENLO PARK.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Octave Bioscience Inc has raised $106M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $33M on 2023-01-04.
Most recent recorded round closed around 2025-03-07.
Valuation (modeled)modeled
Provath models Octave Bioscience Inc at approximately $170M (range $64M–$266M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 16 mo ago; this sector typically re-raises about every 11 months.
Slightly overdue versus sector cadence.
The last round stepped up 4.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotech peers (233 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Goodwin Biotechnology, Inc, Cyrus Biotechnology, Inc., Phylos Bioscience, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.